Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
2002 pubmed

Biochemical and imaging evaluation of Cushing's syndrome.

Newell-Price. J J; Grossman. A A

Key Findings

  • Traditional diagnosis uses urinary free cortisol, low‑dose dexamethasone, and midnight cortisol measurements.
  • Newer differentiation methods include dexamethasone‑suppressed CRH and desmopressin tests, plus refined CRH and GHBP assays.

Practical Outcomes

  • This review offers no actionable guidance for biohackers or N=1 experimenters interested in hexarelin or metabolic optimization. It’s primarily a clinical overview of Cushing's diagnostics, so it isn’t relevant to everyday self‑directed health protocols.

Summary

The abstract reviews how doctors diagnose Cushing's syndrome, focusing on hormone tests and imaging, but it doesn't discuss hexarelin or give any tips you can use for health hacking or performance improvement.

Abstract

The diagnosis and differential diagnosis of Cushing's syndrome remains a considerable challenge in clinical endocrinology. Investigation is a two-step process, involving first diagnosis followed by differential diagnosis. Traditionally diagnosis has relied upon urinary free cortisol (UFC) collection, low-dose dexamethasone-testing, and assessment of midnight cortisol. More recently, differentiation between mild disease and pseudo-Cushing's states has been achieved using dexamethasone-suppressed corticotropin releasing hormone (CRH) and desmopressin tests. Refinements of tests used for differential diagnosis have been made including optimized response criteria for ovine and human sequence CRH tests, desmopressin tests, GHBP-testing and testing with combinations of peptides. Despite improvements in these non-invasive tests use of inferior petrosal or cavernous sinus sampling is frequently required. Imaging is guided by biochemical assessment. MRI is the investigation of choice for Cushing's disease, but is often negative. Scintigraphic investigation using radionucleotide-labeled agonists for receptors commonly expressed by neuroendocrine tumors the investigation of occult ACTH-dependent disease remains disappointing. In this review we critically analyze the tests used for this most challenging of clinical conditions.

Study Information

Provider

pubmed

Year

2002